In this final episode, the experts discuss two patient case studies with oral SERDs (oral selective estrogen receptor degraders) and a novel therapy for ER+/HER2- advanced or metastatic breast cancer. Each patient presents unique and rare situations that shed light on the challenges confronting healthcare professionals and patients alike. They discuss the most up-to-date data and strategies for optimising treatment selection in each individual case.

This podcast is a conversation between two independent experts: Dr. Rena Callahan an Associate Clinical Professor of Hematology Oncology at University of California, Los Angeles David Geffen School of Medicine and Dr. Shaheenah Dawood, a consultant medical oncologist and professor of oncology at Mediclinic City Hospital, United Arab Emirates, Dubai.

This podcast episode provides an introduction to molecular testing in the diagnosis and treatment of cancer.  Prof. David Hong from MD Anderson Cancer Center, Houston, Texas, USA and Dr Tracy Stockley from the University Health Network, Toronto, Canada discuss optimal testing strategies to identify actionable mutations.

The experts discuss genetic testing and why identifying genetic alterations is a critical step to achieving optimal patient care. They share their multidisciplinary perspectives on when to use molecular profiling and which testing methodologies should be used to identify genetic alterations to inform treatment decisions with targeted therapies throughout the patient journey.

In this podcast, the experts deep-dive into two patient case studies of ER+/HER2- metastatic breast cancer, discussing the intricacies of treatment selection and sequencing to maximise outcomes, current data, and what to consider when adjusting dosage or switching treatments.

Dr. Rena Callahan an Associate Clinical Professor of Hematology Oncology at University of California, Los Angeles David Geffen School of Medicine and Dr. Shaheenah Dawood, a consultant medical oncologist and professor of oncology at Mediclinic City Hospital, United Arab Emirates, Dubai discuss oral SERDs, a novel therapy for ER+/HER2- advanced or metastatic breast cancer.

This podcast series consists of two episodes where expert oncologists Dr Sam Klempner (Massachusetts General Hospital, USA) and Dr Lizzy Smyth (Oxford University Hospitals NHS Foundation Trust, UK) discuss patient cases focusing on gastric and gastroesophageal junction cancer. 

In the second episode, Dr Klempner presents a case of a patient with advanced/metastatic gastric cancer.  The two experts discuss biomarker testing such as MMR, HER2, PD-1 and CLDN 18.2. They also discuss treatment options, CPS scoring and test selection plus recent clinical trial data that are practice changing.

This podcast series consists of two episodes where expert oncologists Dr Sam Klempner (Massachusetts General Hospital, USA) and Dr Lizzy Smyth (Oxford University Hospitals NHS Foundation Trust, UK) discuss patient cases focusing on gastric and gastroesophageal junction cancer. 

In this first episode, Dr Smyth presents a case of operable localised gastric cancer.  The two experts discuss the importance of MMR biomarker testing And CROSS VS FLOT management approaches. They refer to data from recent clinical trials in upper gastrointestinal cancer such as MATTERHORN, NEONIPIGA, INFINITY, KEYNOTE-811 and KEYNOTE-585 and how data might impact clinical management. 

In this podcast, the experts give an overview of  the EMERALD trial  and present elacestrant as the first, and currently only, oral SERD to be FDA approved. They focus on the efficacy results and landmark analysis not only according to the duration of CDK4/6i prior treatment but also to the presence/absence of ESR1 mutation. Experts also provide a brief discussion on EMERALD trial safety results. The discussion ends with a look at the current treatment landscapeand future perspective for oral SERDs in ER+/HER2- advanced or metastatic breast cancer.

Dr.Rena Callahan an Associate Clinical Professor of Hematology Oncology at University of California, Los Angeles David Geffen School of Medicine and Dr.Shaheenah Dawood, a consultant medical oncologist and professor of oncology at Mediclinic City Hospital, United Arab Emirates, Dubai explore new endocrine therapies for ER+/HER2- advanced or metastatic breast cancer. More specifically, they discuss  oral SERDs efficacy and safety profile as well as their place in treatment landscape 

In this podcast GU NURSES CONNECT members Brenda Martone and Jennifer Sutton discuss the nurse role in managing treatment intensification for metastatic castration sensitive prostate cancer(mCSPC) patients with triplet therapy of ADT + docetaxel + a novel hormonal agent (NHA).  They focus on patient selection, AE management and drug-drug interactions.

 The experts discuss key data from the PEACE 1 and ARASENS trials of triplet therapy with abiraterone and darolutamide respectively, in combination with ADT and docetaxel. They discuss the importance of the nurse role in communicating and educating the patient about the benefits and risks of different triplet regimens.

 They debate whether triplet therapy should be the new standard of care for all mCSPC patients and discuss the patient subgroups that benefit the most from early treatment intensification.

This podcast episode discusses treatment sequencing in advanced metastatic colorectal cancer (mCRC) patients, third line and beyond.  Dr Shubham Pant from MD Anderson Cancer Center, Houston Texas USA and Dr Jenny Seligmann from the University of Leeds, UK discuss treatment considerations in these patients and evaluate recent data.

 The experts discuss the treatments currently approved at third line – regorafenib and TAS-102 (trifluridine/tipiracil).  They also reflect on data presented at ASCO GI 2023 from the SUNLIGHT trial which studied the use of TAS-102 plus bevacizumab as third-line treatment in refractory colorectal cancer and where this treatment may fit into the treatment sequence in the future.  They also look at data from the FRESCO-2 trial which was presented at ESMO 2022 and studied fruquintinib in the later line mCRC setting..  The discussion then moves to treatments for molecularly selected mCRC patients with the MOUNTAINEER trial where a combination of trastuzumab and tucatinib was studied.  Finally, they discuss EGFR rechallenge and data from the CRICKET and CHRONOS trials. 

Assoc. Prof. Shilpa Gupta and Dr Fabio Schutz, discuss early treatment intensification with triplet therapy for metastatic castration-sensitive prostate cancer (mCSPC) in this GU CONNECT podcast.

The experts discuss how to apply key data from the PEACE 1 and ARASENS trials of triplet therapy with abirateroneand darolutamide respectively, in combination with ADT and docetaxel into their clinical practice. They debate whether triplet therapy should be the new standard of care for all patients and discuss the patient subgroups that benefit the most from early treatment intensification.

A number of patient scenarios are considered alongside the efficacy of the novel hormonal combinations, adverse event profiles, drug to drug interactions, volume of disease, age, comorbidities and patient risk.

Dr Tanya Dorff, a Medical Oncologist from the City of Hope Comprehensive Cancer Center and Dr Neeraj Agarwal, Medical Oncologist and Director of the Genitourinary Oncology Program at the Huntsman Cancer Institute, University of Utah in the United States discuss the efficacy and safety data of combination therapy with PARPi and NHAs, incorporating the latest data presented at ASCO GU 2023 and the impact for the treatment of patients with mCRPC in this GU CONNECT podcast.

In this podcast, the experts discuss the updated survival analysis from the PROPEL study of olaparib and abiraterone which demonstrated a benefit in an all-comer mCRPC population and the second interim analysis from the MAGNITUDE study which showed a benefit of niraparib plus abiraterone in mCRPC patients with homologous recombination repair alterations. They also discuss the differing trial results and how these compare to the most recent data presented from the TALAPRO-2 trial of talazoparib plus enzalutamide which showed a benefit in a biomarker unselected population.

The experts consider how this combination therapy may be implemented in clinical practice in the future pending regulatory approval of the combinations.